Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/2166
Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro
Xiaoyan Pan.
Pengfei Zhou.
Tiejiong Fan.
Yan Wu.
Jing Zhang.
Xiaoyue Shi.
Weijuan Shang.
Lijuan Fang.
Xiaming Jiang.
Jian Shi.
Yuan Sun.
Shaojuan Zhao.
Rui Gong.
Ze Chen.
Gengfu Xiao.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1101/2020.04.07.029884
COVID-19 caused by the emerging human coronavirus, SARS-CoV-2, has become a global pandemic, leading a serious threat to human health. So far, there is none vaccines or specific antiviral drugs approved for that. Therapeutic antibodies for SARS-CoV-2, was obtained from hyper immune equine plasma in this study. Herein, SARS-CoV-2 RBD with gram level were obtained through Chinese hamster ovary cells high-density fermentation. The binding of RBD to SARS-CoV-2 receptor, human ACE2, was verified and the efficacy of RBD in vivo was tested on mice and then on horses. As a result, RBD triggered high-titer neutralizing antibodies in vivo, and immunoglobulin fragment F(ab)2 was prepared from horse antisera through removing Fc. Neutralization test demonstrated that RBD-specific F(ab)2 inhibited SARS-CoV-2 with EC50 at 0.07 g/ml, showing a potent inhibitory effect on SARS-CoV-2. These results highlights as RBD-specific F(ab)2 as therapeutic candidate for SARS-CoV-2.
www.biorxiv.org
2020
Artículo
https://www.biorxiv.org/content/10.1101/2020.04.07.029884v1.full.pdf
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
1101206.pdf1.58 MBAdobe PDFView/Open